Journal of Prevention of Alzheimer's Disease (JPAD) informed Cassava Sciences Inc (NASDAQ: SAVA) about no convincing evidence to support data manipulation allegations in a 2020 paper on simufilam co-authored by the company's personnel and its science collaborators.
Simufilam, Cassava's Alzheimer's candidate, is a small molecule (oral) drug that restores the normal shape and function of altered filamin A protein in the brain.
"From the onset, I have said that allegations of research misconduct are false, and for a good reason – I see no supporting evidence for the allegations," said Remi Barbier, President & CEO.
"I'm hopeful that written pronouncements from neutral and independent science experts will help close the chapter of baseless attacks against our science."
Related Content: Cassava Sciences Shares Plunge After Criminal Investigation Report.
In May 2022, Neurobiology of Aging investigated and found no evidence of data manipulation in a paper on simufilam published in that journal in 2017.
In December 2021, Cassava Sciences announced that Neuroscience investigated and found no evidence of data manipulation in a paper published in 2005.
In November 2021, Cassava Sciences announced that The Journal of Neuroscience investigated and found no evidence of data manipulation in a paper on simufilam published in July 2012.
Price Action: SAVA shares are up 1.79% at $26.18 on the last check Thursday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.